


SUPPLEMENTARY DATA


Supplementary Figure 1. Gleevec blocks ERK-mediated PPAR γ phosphorylation. *In vitro* ERK kinase assay on full-length PPAR γ incubated with rosiglitazone or Gleevec.




SUPPLEMENTARY DATA

Supplementary Figure 2. Gleevec does not activate PPAR α and PPAR δ . Transcriptional activity of a PPAR-derived reporter gene in HEK-293 cells following treatment with GW7647, L165041 or Gleevec.

A




B




SUPPLEMENTARY DATA

Supplementary Figure 3. Gleevec Induced Perturbation in conformational dynamics of PPAR γ detected by HDX-MS. Differential HDX results are mapped onto the PPAR γ crystal structure (3PRG) comparing the apo ligand binding domain of PPAR γ in the presence of either Gleevec or rosiglitazone. 10 μ M of HIS-PPAR γ LBD protein was preincubated with 1:2 molar excess of compounds. 5 μ l of protein solution was mixed with 20 μ l of D₂O-containing HDX buffer (20 mM KPO₄ pH 7.4, 50 mM KCl) and incubated at 4°C for 10s, 30s, 60s, 900s and 3,600s. On-exchange was quenched and the protein denatured with 25 μ l of quench solution (0.1 % v/v TFA in 3 M urea). Samples were then passed through an immobilized pepsin column and the resulting peptides were trapped on a C8 trap column. The bound peptides were gradient-eluted (5-50 % CH₃CN w/v and 0.3 % w/v formic acid) across a C18 HPLC column for 5 min at 4°C. The eluted peptides were subjected to electrospray ionization directly coupled to a high resolution Orbitrap mass spectrometer (Thermo Fisher, MA, USA). Each HDX experiment was carried out in triplicate and the intensity weighted average m/z value (centroid) of each peptide isotopic envelope was calculated with in-house HDX Workbench software.




SUPPLEMENTARY DATA

Supplementary Figure 4. Binding mode of SR1664 or Gleevec to PPAR γ LBD. Docking simulation was performed with crystal structure of PPAR γ LBD (PDB ID: 2hfp) and Discovery Studio[®] 1.7 (Accelrys). The binding pose was predicted by docking simulation using the Discovery Studio 1.7[®] program. PPAR γ ligand-binding pockets were defined from receptor cavities, and the LigandFit module implemented in the Receptor-Ligand Interaction protocol was used for detailed calculations. X-ray crystal structure of PPAR γ ligand binding domain (2hfp) was used in the docking simulation and the subsequent structural analysis with the Discovery Studio Visualizer 3.0[®] program (Accelrys Software Inc., CA, USA).



SUPPLEMENTARY DATA


Supplementary Figure 5. The effect of Gleevec on blood glucose level and plasma level of triglyceride and free fatty acid in HFD-fed mice. Fed blood glucose level (A) and serum level of triglyceride (B) and FFAs (C) in HFD mice treated with Gleevec for 7 days or 21 days (same as in Fig. 3C). Error bars are S.E.M. *** $p < 0.001$ compared with vehicle



SUPPLEMENTARY DATA


Supplementary Figure 6. The effect of Gleevec on inflammation in adipocytes and macrophages.

Fully differentiated 3T3-L1 adipocytes (A) and primary macrophages isolated from bone-marrow (B) were treated with Gleevec for 24 h and stimulated with TNF-a (50 ng/ml) for 3 h or LPS (10 ng/ml) for 6 h, respectively. Expression of pro-inflammatory cytokines was determined by qPCR (n=3). (C) Migratory capacity of Raw264.7 macrophages were measured using an *in vitro* transwell chemotaxis assay (n=5). Mature 3T3-L1 adipocytes were used for preparation of conditioned media (CM). 3T3-L1 adipocytes were stimulated by TNF-a (10 ng/ml) for 24 h after pre-treatment with the indicated concentration of Gleevec for 24 h in serum-free DMEM. For the migration, 100,000 Raw264.7 cells were placed in the upper chamber of a 5 µm polycarbonate filter (24-transwell format; Corning, Lowell, MA, USA), whereas adipocyte conditioned medium or MCP-1 (10 ng/ml) treatment was placed in the lower chamber. After 3 h of migration, cells were fixed in formalin and stained with 4', 6-diamidino-2-phenylindole and observed. All of represented error bars are S.E.M. **p*<0.05, ***p*<0.01, ****p*<0.001 compared with vehicle.




SUPPLEMENTARY DATA

Supplementary Figure 7. The effect of Gleevec on respiratory exchange ratio (RER) in HFD-fed mice. The RER for 5 days in HFD-fed mice treated with Gleevec for 21 days (A) and the average quantification for 12 h light and 12 h dark period in A.



SUPPLEMENTARY DATA

Supplementary Figure 8. The effect of gleevec on thermogenic program in brown adipose tissue (BAT) of HFD-fed mice. Expression of thermogenic and β -oxidation genes was determined by qPCR in interscapular brown adipose tissue (BAT) of gleevec-treated HFD-fed mice for 21 days without (A) or with 9 h cold challenge (B). Error bars are S.E.M. (n=7). * p <0.05, ** p <0.01 and *** p <0.001 compared with vehicle.



SUPPLEMENTARY DATA

Supplementary Figure 9. The effect of Gleevec on *Ucp-1* and *Pgc-1 α* in isolated stromal vascular fraction (SVF) of sWAT. Fully differentiated sWAT SVF cells were treated with Gleevec for 3 days. Expression of *Ucp-1* and *Pgc-1 α* were determined by qPCR following treatment of forskolin (10 μ M) for 4 h. Error bars are S.E.M. (n=3). *** p <0.001 compared with forskolin-untreated vehicle. n.s, not significant

